Navigation Links
Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies

ST. LOUIS, Oct. 4 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) announced today that it has entered into a collaboration with the Institute of Research in Immunology and Cancer (IRIC) of the Universite de Montreal. This collaboration, made possible through grants from Genome Quebec and contributions by Sigma-Aldrich, will leverage Sigma's RNA Interference (RNAi) technologies for the purpose of identifying potential new drug targets.

Sigma-Aldrich and the Universite de Montreal have signed an agreement whereby the Institute's High Throughput Screening facility gains access to Sigma-Aldrich's RNAi intellectual property portfolio and its MISSION(R) shRNA library collection for both human and mouse genomes. This agreement marks the latest of a number of licensing and research collaborations the company has made as an ongoing commitment to bring cutting-edge technologies to researchers worldwide. By adopting the MISSION(R) shRNA library as their platform for RNAi screening, The University of Montreal will be utilizing the collective expertise of The RNAi Consortium (TRC), which consists of a partnership among the Broad Institute, MIT, Harvard, Dana Farber, Sigma- Aldrich as well as other research organizations and major pharmaceutical companies. In exchange, Sigma-Aldrich plans to utilize feedback from the collaboration to further its understanding of specific target function and to continue the development of tools for high throughput drug discovery.

"We are eager to work with the Universite de Montreal to provide researchers access to the Sigma-Aldrich MISSION(R) RNAi portfolio of products and intellectual property," said David Smoller, Ph.D., President of Sigma- Aldrich's Research Biotechnology business unit. "RNAi is becoming the leading technology used by researchers for the advancement of drug discovery, commitment to this technology by the University and the investment of Canadian government positions the facility to be a leader in this effort."

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 7,700 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award- winning Web site at

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies' expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies' operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.

SOURCE Sigma-Aldrich
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Strandware Founder Establishes Consulting Firm
2. RedPrairie Establishes Asia-Pacific Headquarters in Shanghai
3. West Coast VC Establishes Midwest Presence in Madison
4. Regional collaboration is key to states future
5. Cieslewicz, Barrett talk economic collaboration
6. Congress passes bill to ease researchers collaboration worries
7. Economic collaboration in Denver sets tall goal for Wisconsin
8. Better collaboration urged to further Wisconsin biotech
9. Southeastern Wisconsin Technology Collaboration
10. Big collaboration links learners to science on a tiny scale
11. UW-Madison releases open 3D collaboration environment
Post Your Comments:
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be ... York on Wednesday, December 2 at 9:30 a.m. ET/6:30 ... CEO, will provide a corporate overview. th Annual ... 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola , ... corporate overview. --> th Annual Oppenheimer Healthcare Conference ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
(Date:11/24/2015)... ... 24, 2015 , ... The Academy of Model Aeronautics (AMA), led by its ... as Multirotor Grand Prix, to represent the First–Person View (FPV) racing community. , FPV ... embraced this type of racing and several new model aviation pilots have joined the ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris , qui s,est tenu ... Paris , qui s,est tenu du 17 au ... l,innovation biométrique, a inventé le premier scanner couplé, qui ... même surface de balayage. Jusqu,ici, deux scanners étaient nécessaires, ... digitales. Désormais, un seul scanner est en mesure de ...
(Date:11/12/2015)... golden retriever that stayed healthy despite having the gene ... new lead for treating this muscle-wasting disorder, report scientists ... and Harvard and the University of São Paolo in ... pinpoints a protective gene that boosts muscle regeneration, ... Children,s lab of Lou Kunkel , PhD, is ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
Breaking Biology News(10 mins):